Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies

BACKGROUND: Cognitive impairment is a core feature of schizophrenia. While first- and second-generation antipsychotic drugs treat psychotic exacerbations, no treatment is approved for the cognitive dysfunction. We have identified ASP4345, a positive allosteric modulator of the dopamine type 1 (D(1))...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Amit, Benner, Lauren, Wu, Ruishan, Gertsik, Lev, Uz, Tolga, Marek, Gerard J., Zhu, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808976/
https://www.ncbi.nlm.nih.gov/pubmed/32533536
http://dx.doi.org/10.1007/s40262-020-00911-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808976/
https://www.ncbi.nlm.nih.gov/pubmed/32533536
http://dx.doi.org/10.1007/s40262-020-00911-0

Ejemplares similares